Issuer Client News

News & Events

Aerami Therapeutics to Present at the LifeSci Partners Summer Symposium

Aerami Therapeutics to Present at the LifeSci Partners Summer Symposium

DURHAM, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (the “Company”) announced today that Anne Whitaker, Chief Executive Officer, will present a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners, on August 4 and 5, 2020. Please click the following link to register: https://lifesci.events/SummerSymposium

Presentation Details:
Date: August 5, 2020
Time: 9:00 am Eastern Time

About Aerami Therapeutics
Aerami Therapeutics is developing a new generation of inhaled therapies for the treatment of severe respiratory diseases. Our lead product candidate is an inhaled formulation of imatinib (AER-901) delivered via a proprietary handheld nebulizer for the treatment of patients with pulmonary arterial hypertension (PAH), a progressive and currently incurable lung disease. AER-901 has the potential to advance the treatment paradigm for patients with PAH by slowing the progression of the disease. In addition to PAH, we plan to explore additional indications for AER-901 based on imatinib’s mechanism of action. We believe respiratory drugs that are specifically designed for inhalation can offer significant benefits compared to other routes of administration. Our product development approach pairs inhaled formulations of existing drugs with proven therapeutic benefit with device technology that optimizes delivery through the lungs to improve safety and clinical outcomes for diseases with high unmet needs. For more information, please visit www.aerami.com.

Contact:
Investor Relations
Jeremy Feffer
Managing Director
LifeSci Advisors, LLC
T: + 1-212-915-2568
jeremy@lifesciadvisors.com

Media Relations
Mónica Rouco Molina
Account Executive
LifeSci Communications
T: +1-929-469-3850
mroucomolina@lifescicomms.com


new logo.png

Source: Aerami Therapeutics

Brokerage and investment advisory products and services, are offered through Aegis Capital Corp, a member of FINRA and SIPC. Insurance products are made available through, ACC General Agency, a licensed insurance agency. For those persons inquiring from states where a specific associate is not currently securities and/or insurance licensed, the associate will not transact business in that state or provide follow-up individual responses, until after the associate obtains the appropriate registration in the applicable state.

The information provided should not be relied upon in isolation for the purpose of making an investment decision. You must also consider the objectives, risks, charges, and expenses associated with an investment service, product or strategy prior to making an investment decision. Prior to making any investment or financial decision, an investor should seek advice from a financial, legal, tax and other professional that consider all of the particular facts and circumstances of an investor's situation. The opinions expressed and material provided are for information purposes only and is not an offer, recommendation, or solicitation of any product, strategy or transaction. Any views, strategies or products discussed may not be appropriate or suitable for all individuals and are subject to risks.

Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.

Check the background of your financial professional on FINRA's BrokerCheck

Form CRS and General Disclosures

Aegis Risk Disclosures